{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS03+Adjuvant&page=2", "query": { "intervention": "AS03 Adjuvant", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS03+Adjuvant&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T06:02:56.876Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04636697", "title": "Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "SARS-CoV-2 Infection" ], "interventions": [ { "name": "Intramuscular injection", "type": "DRUG" }, { "name": "Intramuscular vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Medicago", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30918, "start_date": "2020-11-19", "completion_date": "2022-04-30", "has_results": false, "last_update_posted_date": "2022-04-06", "last_synced_at": "2026-09-24T06:02:56.876Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04636697" }, { "nct_id": "NCT03275389", "title": "A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "D-SUIV cH8/1N1+AS03", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH5/1N1+AS03", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH11/1N1+AS03", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH8/1N1+AS01", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH5/1N1+AS01", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH11/1N1+AS01", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH8/1N1", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH5/1N1", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH11/1N1", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Fluarix Quadrivalent", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 470, "start_date": "2017-09-08", "completion_date": "2020-03-26", "has_results": true, "last_update_posted_date": "2021-05-07", "last_synced_at": "2026-09-24T06:02:56.876Z", "location_count": 5, "location_summary": "South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more", "locations": [ { "city": "South Miami", "state": "Florida" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Rochester", "state": "New York" }, { "city": "Austin", "state": "Texas" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275389" }, { "nct_id": "NCT03300050", "title": "Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza", "Vaccine" ], "interventions": [ { "name": "cH8/1N1 LAIV", "type": "BIOLOGICAL" }, { "name": "AS03-adjuvanted cH5/1N1 IIV", "type": "BIOLOGICAL" }, { "name": "cH5/1N1 IIV", "type": "BIOLOGICAL" }, { "name": "AS03-adjuvanted cH8/1N1 IIV", "type": "BIOLOGICAL" }, { "name": "Normal saline", "type": "BIOLOGICAL" }, { "name": "Phosphate buffered saline (PBS)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "PATH", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 65, "start_date": "2017-10-10", "completion_date": "2019-08-09", "has_results": true, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-09-24T06:02:56.876Z", "location_count": 2, "location_summary": "Durham, North Carolina • Cincinnati, Ohio", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03300050" }, { "nct_id": "NCT02624219", "title": "H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Avian Influenza", "Influenza" ], "interventions": [ { "name": "AS03", "type": "DRUG" }, { "name": "MF59 adjuvant", "type": "DRUG" }, { "name": "Monovalent Influenza A/H5N8 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "19 Years to 64 Years" }, "enrollment_count": 276, "start_date": "2016-08-16", "completion_date": "2018-01-30", "has_results": false, "last_update_posted_date": "2019-10-23", "last_synced_at": "2026-09-24T06:02:56.876Z", "location_count": 4, "location_summary": "Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02624219" }, { "nct_id": "NCT05975840", "title": "Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "FLU Q-PAN H5N8 375_B", "type": "BIOLOGICAL" }, { "name": "FLU Q-PAN H5N8 375_A", "type": "BIOLOGICAL" }, { "name": "FLU Q-PAN H5N8 750_B", "type": "BIOLOGICAL" }, { "name": "FLU Q-PAN H5N8 750_A", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2023-08-03", "completion_date": "2024-09-19", "has_results": true, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-09-24T06:02:56.876Z", "location_count": 20, "location_summary": "Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 17 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05975840" }, { "nct_id": "NCT01578317", "title": "Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "H5N1 vaccine plus AS03 adjuvant", "type": "BIOLOGICAL" }, { "name": "H5N1 vaccine without adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 43, "start_date": "2012-03-20", "completion_date": "2016-01-31", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-09-24T06:02:56.876Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01578317" }, { "nct_id": "NCT01573312", "title": "H5N1 Vaccination With and Without AS03: Systems Biology Analysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "ASO3 Adjuvant", "type": "DRUG" }, { "name": "Influenza A/H5N1 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 20, "start_date": "2012-05-24", "completion_date": "2014-01-02", "has_results": false, "last_update_posted_date": "2019-10-21", "last_synced_at": "2026-09-24T06:02:56.876Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01573312" }, { "nct_id": "NCT04537208", "title": "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "COVID-19 (Healthy Volunteers)" ], "interventions": [ { "name": "CoV2 preS dTM-AF03 (low-dose)", "type": "BIOLOGICAL" }, { "name": "CoV2 preS dTM-AF03 (high-dose)", "type": "BIOLOGICAL" }, { "name": "CoV2 preS dTM-AS03 (low-dose)", "type": "BIOLOGICAL" }, { "name": "CoV2 preS dTM-AS03 (high-dose)", "type": "BIOLOGICAL" }, { "name": "CoV2 preS dTM (high-dose) without adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo (0.9% normal saline)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 441, "start_date": "2020-09-03", "completion_date": "2021-11-19", "has_results": true, "last_update_posted_date": "2025-09-17", "last_synced_at": "2026-09-24T06:02:56.876Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04537208" }, { "nct_id": "NCT03738241", "title": "2017 A/H7N9 IIV Revaccination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Avian Influenza", "Influenza Immunisation" ], "interventions": [ { "name": "A/H7N9", "type": "BIOLOGICAL" }, { "name": "AS03", "type": "DRUG" }, { "name": "Phosphate Buffered Saline (PBS) diluent", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "19 Years to 70 Years" }, "enrollment_count": 304, "start_date": "2018-12-18", "completion_date": "2020-06-19", "has_results": true, "last_update_posted_date": "2021-07-30", "last_synced_at": "2026-09-24T06:02:56.876Z", "location_count": 9, "location_summary": "Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03738241" }, { "nct_id": "NCT01949090", "title": "Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Investigational H7N1 vaccine GSK2789869A", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 363, "start_date": "2013-09-25", "completion_date": "2014-10-23", "has_results": true, "last_update_posted_date": "2017-11-17", "last_synced_at": "2026-09-24T06:02:56.876Z", "location_count": 5, "location_summary": "Hollywood, Florida • Meridian, Idaho • Lenexa, Kansas + 2 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Meridian", "state": "Idaho" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01949090" } ] }